bluebird reports updated Phase I data for bb2121 in MM

bluebird bio Inc. (NASDAQ:BLUE) reported updated data from the Phase I CRB-401 trial evaluating its CAR T cell therapy bb2121 in patients with relapsed or refractory multiple myeloma. The data were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

Among 18 patients in the dose-escalation portion who received an active dose of bb2121 (≥150x10⁶ CAR T cells), median progression-free survival (PFS) was 11.8 months vs. 2.7 months in patients who received a lower inactive dose of bb2121. Among 16 patients who were negative for minimal residual disease (MRD), median PFS was 17.7 months...